These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

184 related articles for article (PubMed ID: 28954755)

  • 61. Severe disease activity in MS patients treated with cladribine after fingolimod withdrawal.
    Cellerino M; Bonavita S; Ferrero M; Inglese M; Boffa G
    J Neurol Sci; 2020 Nov; 418():117156. PubMed ID: 33010653
    [No Abstract]   [Full Text] [Related]  

  • 62. Efficacy of fingolimod in patients with highly active relapsing-remitting multiple sclerosis.
    Derfuss T; Bergvall NK; Sfikas N; Tomic DL
    Curr Med Res Opin; 2015; 31(9):1687-91. PubMed ID: 26121423
    [TBL] [Abstract][Full Text] [Related]  

  • 63. Detection of a new melanoma in a patient treated with fingolimod.
    Michiels Y; Bugnon O; Michiels JF; Mazellier S
    BMJ Case Rep; 2019 Apr; 12(4):. PubMed ID: 31036735
    [TBL] [Abstract][Full Text] [Related]  

  • 64. Outcomes of switching directly to oral fingolimod from injectable therapies: Results of the randomized, open-label, multicenter, Evaluate Patient OutComes (EPOC) study in relapsing multiple sclerosis.
    Fox E; Edwards K; Burch G; Wynn DR; LaGanke C; Crayton H; Hunter SF; Huffman C; Kim E; Pestreich L; McCague K; Barbato L;
    Mult Scler Relat Disord; 2014 Sep; 3(5):607-19. PubMed ID: 26265273
    [TBL] [Abstract][Full Text] [Related]  

  • 65. Acetazolamide therapy in a case of fingolimod-associated macular edema: early benefits and long-term limitations.
    Schröder K; Finis D; Harmel J; Ringelstein M; Hartung HP; Geerling G; Aktas O; Guthoff R
    Mult Scler Relat Disord; 2015 Sep; 4(5):406-408. PubMed ID: 26346788
    [TBL] [Abstract][Full Text] [Related]  

  • 66. Primary mediastinal large B-cell lymphoma in a patient on Fingolimod for relapsing-remitting multiple sclerosis.
    Chacko JA; Strati P; Stout PW; Archer RL; Baltz BP; Chacko JG
    Mult Scler Relat Disord; 2021 Apr; 49():102776. PubMed ID: 33508568
    [TBL] [Abstract][Full Text] [Related]  

  • 67. A placebo-controlled trial of oral fingolimod in relapsing multiple sclerosis.
    Kappos L; Radue EW; O'Connor P; Polman C; Hohlfeld R; Calabresi P; Selmaj K; Agoropoulou C; Leyk M; Zhang-Auberson L; Burtin P;
    N Engl J Med; 2010 Feb; 362(5):387-401. PubMed ID: 20089952
    [TBL] [Abstract][Full Text] [Related]  

  • 68. Complicated Monkeypox Infection in a Patient With Multiple Sclerosis and Fingolimod Treatment.
    Müller-Jensen L; Kriedemann H; Anvari K; Huehnchen P; Siffrin V
    Neurology; 2023 Apr; 100(14):670-671. PubMed ID: 36539295
    [TBL] [Abstract][Full Text] [Related]  

  • 69. Benefit-Risk Profile of Sphingosine-1-Phosphate Receptor Modulators in Relapsing and Secondary Progressive Multiple Sclerosis.
    Comi G; Hartung HP; Bakshi R; Williams IM; Wiendl H
    Drugs; 2017 Oct; 77(16):1755-1768. PubMed ID: 28905255
    [TBL] [Abstract][Full Text] [Related]  

  • 70. [Early onset of fingolimod-associated macular edema].
    Schelenz D; Kleiter I; Schöllhammer J; Rehrmann J; Elling M; Dick HB; Kakkassery V
    Ophthalmologe; 2018 May; 115(5):424-428. PubMed ID: 28653209
    [TBL] [Abstract][Full Text] [Related]  

  • 71. First-dose effects of fingolimod after switching from injectable therapies in the randomized, open-label, multicenter, Evaluate Patient OutComes (EPOC) study in relapsing multiple sclerosis.
    Hughes B; Cascione M; Freedman MS; Agius M; Kantor D; Gudesblatt M; Goldstick LP; Agashivala N; Schofield L; McCague K; Hashmonay R; Barbato L;
    Mult Scler Relat Disord; 2014 Sep; 3(5):620-8. PubMed ID: 26265274
    [TBL] [Abstract][Full Text] [Related]  

  • 72. Severe fingolimod rebound syndrome after switching to cladribine treatment.
    Coss-Rovirosa F; Salado-Burbano J; Casallas-Vanegas A; Caire-Herrera LE; Gómez-Figueroa E; Flores-Rivera J
    Mult Scler Relat Disord; 2020 May; 40():101938. PubMed ID: 31982666
    [TBL] [Abstract][Full Text] [Related]  

  • 73. A Swiss real world best practice experience in three different clinical settings of the 6 hour fingolimod first dose observation procedure.
    Ramseier SP; Roth S; Czaplinski A
    BMC Pharmacol Toxicol; 2015 Apr; 16():7. PubMed ID: 25889400
    [TBL] [Abstract][Full Text] [Related]  

  • 74. Immune thrombocytopenic purpura associated with fingolimod.
    Yuen HLA; Brown S; Chan N; Grigoriadis G
    BMJ Case Rep; 2017 Sep; 2017():. PubMed ID: 28893804
    [TBL] [Abstract][Full Text] [Related]  

  • 75. Response to letter regarding article 'Fingolimod effects on left ventricular function in multiple sclerosis'.
    Racca V; Di Rienzo M; Cavarretta R; Toccafondi A; Vaini E; Ferratini M; Rovaris M
    Mult Scler; 2016 Apr; 22(5):708-9. PubMed ID: 26359278
    [No Abstract]   [Full Text] [Related]  

  • 76. Early safety and efficacy of fingolimod treatment in Denmark.
    Voldsgaard A; Koch-Henriksen N; Magyari M; Sellebjerg F; Sørensen PS; Oturai AB
    Acta Neurol Scand; 2017 Jan; 135(1):129-133. PubMed ID: 27910101
    [TBL] [Abstract][Full Text] [Related]  

  • 77. Comment on "Fingolimod effects on left ventricular function in multiple sclerosis" Mult Scler 2015.
    Bakshi R; Häring DA
    Mult Scler; 2016 Apr; 22(5):707-8. PubMed ID: 26359277
    [No Abstract]   [Full Text] [Related]  

  • 78. Index of cardiac-electrophysiological balance in relapsing-remitting multiple sclerosis patients treated with fingolimod.
    Gunay-Polatkan S; Gullu G; Sigirli D; Koc ER; Aydinlar A; Turan OF
    Mult Scler Relat Disord; 2023 Aug; 76():104827. PubMed ID: 37331085
    [TBL] [Abstract][Full Text] [Related]  

  • 79. Comparison of efficacy and safety of oral agents for the treatment of relapsing-remitting multiple sclerosis.
    Guarnera C; Bramanti P; Mazzon E
    Drug Des Devel Ther; 2017; 11():2193-2207. PubMed ID: 28814828
    [TBL] [Abstract][Full Text] [Related]  

  • 80. Cryptococcal meningoencephalitis in a multiple sclerosis patient after fingolimod discontinuation-a case report.
    Baghbanian SM; Amiri MRM
    Neurol Sci; 2021 Mar; 42(3):1175-1177. PubMed ID: 32968870
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.